UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Targeting glutamine metabolism in multiple myeloma enhances BIM binding to BCL-2 eliciting synthetic lethality to venetoclax

Oncogene, 2016-07, Vol.35 (30), p.3955-3964

2016

Volltextzugriff (PDF)

Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies

Haematologica (Roma), 2013-11, Vol.98 (11), p.1753-1761

2013

Volltextzugriff (PDF)

Dexamethasone treatment promotes Bcl-2 dependence in multiple myeloma resulting in sensitivity to venetoclax

Leukemia, 2016-05, Vol.30 (5), p.1086-1093

2016

Volltextzugriff (PDF)

Consolidation and maintenance therapy with lenalidomide, bortezomib and dexamethasone (RVD) in high-risk myeloma patients

Leukemia, 2014-03, Vol.28 (3), p.690-693

2014

Volltextzugriff (PDF)

Frequency and Risk Factors Associated With Osteonecrosis of the Jaw in Cancer Patients Treated With Intravenous Bisphosphonates

Journal of bone and mineral research, 2008-06, Vol.23 (6), p.826-836

2008

Volltextzugriff (PDF)

Examination of the follicular lymphoma international prognostic index (FLIPI) in the National LymphoCare study (NLCS): a prospective US patient cohort treated predominantly in community practices

Annals of oncology, 2013-02, Vol.24 (2), p.441-448

2013

Volltextzugriff (PDF)

Guidance for Use and dosing of Selinexor in Multiple Myeloma in 2021: Consensus From International Myeloma Foundation Expert Roundtable

Clinical lymphoma, myeloma and leukemia, 2022-07, Vol.22 (7), p.e526-e531

2022

Volltextzugriff (PDF)

Pomalidomide, bortezomib and low-dose dexamethasone in lenalidomide-refractory and proteasome inhibitor-exposed myeloma

Leukemia, 2017-12, Vol.31 (12), p.2695-2701

2017

Volltextzugriff (PDF)

EFFICACY AND SAFETY OF ELRANATAMAB BY AGE AND FRAILTY IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: A SUBGROUP ANALYSIS FROM MAGNETISMM-3

Hematology, Transfusion and Cell Therapy, 2023-10, Vol.45, p.S406-S407

2023

Volltextzugriff (PDF)

Correction: Pomalidomide, bortezomib, and low-dose dexamethasone in lenalidomide-refractory and proteasome inhibitor-exposed myeloma

Leukemia, 2018-10, Vol.32 (10), p.2305-2305

2018

Volltextzugriff (PDF)

Favorable impact of pre-transplant ATG on outcomes of reduced-intensity hematopoietic cell transplants from partially mismatched unrelated donors

Bone marrow transplantation (Basingstoke), 2014-02, Vol.49 (2), p.185-189

2014

Volltextzugriff (PDF)

Tuberculosis in umbilical cord blood transplant recipients: clinical characteristics and challenges

Bone marrow transplantation (Basingstoke), 2015-03, Vol.50 (3), p.465-468

2015

Volltextzugriff (PDF)

Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma

The New England journal of medicine, 2022-07, Vol.387 (2), p.132-147

2022

Volltextzugriff (PDF)

EFFICACY AND SAFETY OF ELRANATAMAB IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA AND PRIOR B-CELL MATURATION ANTIGEN–DIRECTED THERAPIES: A POOLED ANALYSIS FROM MAGNETISMM STUDIES

Hematology, Transfusion and Cell Therapy, 2023-10, Vol.45, p.S405

2023

Volltextzugriff (PDF)

ELRANATAMAB, A B-CELL MATURATION ANTIGEN-CD3 BISPECIFIC ANTIBODY, FOR PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: EXTENDED FOLLOW UP AND BIWEEKLY ADMINISTRATION FROM THE MAGNETISMM-3 STUDY

Hematology, Transfusion and Cell Therapy, 2023-10, Vol.45, p.S404-S405

2023

Volltextzugriff (PDF)

PB2020: MAJESTEC‐3: RANDOMIZED, PHASE 3 STUDY OF TECLISTAMAB PLUS DARATUMUMAB VERSUS DPD OR DVD IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

HemaSphere, 2022-06, Vol.6 (Suppl), p.1891-1892

2022

Volltextzugriff (PDF)

Characterization of Heat Shock Factor 1 in Response to Proteasome Inhibition Unveils a Novel Therapeutic Strategy for Multiple Myeloma Treatment

Clinical lymphoma, myeloma and leukemia, 2015-09, Vol.15, p.e244-e245

2015

Volltextzugriff (PDF)

P31 SINGLE‐AGENT BELANTAMAB MAFODOTIN IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA: FINAL ANALYSIS OF THE DREAMM‐2 TRIAL

HemaSphere, 2023-05, Vol.7 (S2), p.27-28

2023

Volltextzugriff (PDF)

Comparable outcomes following two or three cycles of high-dose chemotherapy and autologous stem cell transplantation for patients with relapsed/refractory germ cell tumors

Bone marrow transplantation (Basingstoke), 2017-01, Vol.52 (1), p.132-134

2017

Volltextzugriff (PDF)

P939: SYNERGISTIC EFFECTS OF LOW DOSE BELANTAMAB MAFODOTIN IN COMBINATION WITH A GAMMA‐SECRETASE INHIBITOR (NIROGACESTAT) IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): DREAMM‐5 STUDY

HemaSphere, 2022-06, Vol.6 (Suppl), p.829-830

2022

Volltextzugriff (PDF)

S184: EVALUATING TECLISTAMAB IN PATIENTS WITH RELAPSED/ REFRACTORY MULTIPLE MYELOMA FOLLOWING EXPOSURE TO OTHER B‐CELL MATURATION ANTIGEN (BCMA)‐TARGETED AGENTS

HemaSphere, 2022-06, Vol.6, p.85-86

2022

Volltextzugriff (PDF)

Cost-effectiveness of lenalidomide plus dexamethasone vs bortezomib plus melphalan and prednisone in transplant-ineligible US patients with newly-diagnosed multiple myeloma

Journal of medical economics, 2016-03, Vol.19 (3), p.243-258

2016

Volltextzugriff (PDF)

CARFILZOMIB, DEXAMETHASONE, AND DARATUMUMAB VERSUS CARFILZOMIB AND DEXAMETHASONE IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA: SUBGROUP ANALYSIS OF THE PHASE 3 CANDOR STUDY BY NUMBER OF PRIOR LINES OFTHERAPY AND PRIOR THERAPIES

Hematology, Transfusion and Cell Therapy, 2020-11, Vol.42, p.253-254

2020

Volltextzugriff (PDF)

P06: UPDATED RESULTS FROM THE PHASE 1/2 MAJESTEC‐1 STUDY OF TECLISTAMAB, A B‐CELL MATURATION ANTIGEN X CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

HemaSphere, 2022-04, Vol.6 (Suppl), p.14-14

2022

Volltextzugriff (PDF)

DARATUMUMAB, BORTEZOMIB AND DEXAMETHASONE (DVD) VS BORTEZOMIB AND DEXAMETHASONE (VD) IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): EFFICACY AND SAFETY UPDATE (CASTOR)

Hematological oncology, 2017-06, Vol.35 (S2), p.388-389

2017

Volltextzugriff (PDF)

1 – 25 von 616

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(553)
Mit Volltextzugriff
(537)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Englisch
(616)
Japanisch
(2)

Erscheinungsjahr

n.n

Thema

Science & Technology
(193)
Life Sciences & Biomedicine
(177)
Humans
(140)
Oncology
(123)
Multiple Myeloma
(89)
Hematology
(79)
Multiple Myeloma - Drug Therapy
(77)
Male
(60)
Female
(59)
Aged
(57)
Middle Aged
(54)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(47)
Adult
(46)
Treatment Outcome
(34)
Patients
(32)
Bortezomib
(31)
Multiple Myeloma - Therapy
(29)
Immunotherapy
(25)
Myeloma
(25)
Antineoplastic Combined Chemotherapy Protocols - Adverse Effects
(23)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(23)
... seit 30 Tagen
(10)

Menü

Weitere Dienste

Einstellungen

Targeting glutamine metabolism in multiple myeloma enhances BIM binding to BCL-2 eliciting synthetic lethality to venetoclax

Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies

Dexamethasone treatment promotes Bcl-2 dependence in multiple myeloma resulting in sensitivity to venetoclax

Consolidation and maintenance therapy with lenalidomide, bortezomib and dexamethasone (RVD) in high-risk myeloma patients

Frequency and Risk Factors Associated With Osteonecrosis of the Jaw in Cancer Patients Treated With Intravenous Bisphosphonates

Examination of the follicular lymphoma international prognostic index (FLIPI) in the National LymphoCare study (NLCS): a prospective US patient cohort treated predominantly in community practices

Guidance for Use and dosing of Selinexor in Multiple Myeloma in 2021: Consensus From International Myeloma Foundation Expert Roundtable

Pomalidomide, bortezomib and low-dose dexamethasone in lenalidomide-refractory and proteasome inhibitor-exposed myeloma

EFFICACY AND SAFETY OF ELRANATAMAB BY AGE AND FRAILTY IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: A SUBGROUP ANALYSIS FROM MAGNETISMM-3

Correction: Pomalidomide, bortezomib, and low-dose dexamethasone in lenalidomide-refractory and proteasome inhibitor-exposed myeloma

Favorable impact of pre-transplant ATG on outcomes of reduced-intensity hematopoietic cell transplants from partially mismatched unrelated donors

Tuberculosis in umbilical cord blood transplant recipients: clinical characteristics and challenges

Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma

EFFICACY AND SAFETY OF ELRANATAMAB IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA AND PRIOR B-CELL MATURATION ANTIGEN–DIRECTED THERAPIES: A POOLED ANALYSIS FROM MAGNETISMM STUDIES

ELRANATAMAB, A B-CELL MATURATION ANTIGEN-CD3 BISPECIFIC ANTIBODY, FOR PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: EXTENDED FOLLOW UP AND BIWEEKLY ADMINISTRATION FROM THE MAGNETISMM-3 STUDY

PB2020: MAJESTEC‐3: RANDOMIZED, PHASE 3 STUDY OF TECLISTAMAB PLUS DARATUMUMAB VERSUS DPD OR DVD IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

Characterization of Heat Shock Factor 1 in Response to Proteasome Inhibition Unveils a Novel Therapeutic Strategy for Multiple Myeloma Treatment

P31 SINGLE‐AGENT BELANTAMAB MAFODOTIN IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA: FINAL ANALYSIS OF THE DREAMM‐2 TRIAL

Comparable outcomes following two or three cycles of high-dose chemotherapy and autologous stem cell transplantation for patients with relapsed/refractory germ cell tumors

P939: SYNERGISTIC EFFECTS OF LOW DOSE BELANTAMAB MAFODOTIN IN COMBINATION WITH A GAMMA‐SECRETASE INHIBITOR (NIROGACESTAT) IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): DREAMM‐5 STUDY

S184: EVALUATING TECLISTAMAB IN PATIENTS WITH RELAPSED/ REFRACTORY MULTIPLE MYELOMA FOLLOWING EXPOSURE TO OTHER B‐CELL MATURATION ANTIGEN (BCMA)‐TARGETED AGENTS

Cost-effectiveness of lenalidomide plus dexamethasone vs bortezomib plus melphalan and prednisone in transplant-ineligible US patients with newly-diagnosed multiple myeloma

CARFILZOMIB, DEXAMETHASONE, AND DARATUMUMAB VERSUS CARFILZOMIB AND DEXAMETHASONE IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA: SUBGROUP ANALYSIS OF THE PHASE 3 CANDOR STUDY BY NUMBER OF PRIOR LINES OFTHERAPY AND PRIOR THERAPIES

P06: UPDATED RESULTS FROM THE PHASE 1/2 MAJESTEC‐1 STUDY OF TECLISTAMAB, A B‐CELL MATURATION ANTIGEN X CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

DARATUMUMAB, BORTEZOMIB AND DEXAMETHASONE (DVD) VS BORTEZOMIB AND DEXAMETHASONE (VD) IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): EFFICACY AND SAFETY UPDATE (CASTOR)

Suchergebnisse filtern